Acute Radiation Syndrome Pipeline Insight
DelveInsight’s, “Acute Radiation Syndrome – Pipeline Insights, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Acute Radiation Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Acute Radiation Syndrome Understanding
Acute Radiation Syndrome: Overview
Acute Radiation Syndrome (ARS) also known as radiation toxicity or radiation sickness is an illness when a person’s whole body or a significant portion of body is exposed to high levels of radiation for a short period of time. The amount of radiation that a person’s body absorbs is called the radiation dose. The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Types of radiation that can cause ARS include alpha radiation particles, beta radiation particles - charged particles (electrons), gamma rays, x-rays, neutrons etc.
The effects of exposure to radiations are nonspecific signs and symptoms such as nausea, emesis, fatigue, fever, Diarrhea, Headache, Dizziness and disorientation, Hair loss, Bloody vomit and stools from internal bleeding, low blood pressure and anorexia. The severity of symptoms depends on how much radiation was absorbed, the strength of the radiated energy, the time of exposure, and the distance between body and the source of radiation. The severity of radiation sickness also depends on sensitivity of the affected tissue like the gastrointestinal system and bone marrow are highly sensitive to radiation.
A diagnosis of Acute Radiation Syndrome without any history of exposure to radiation is complicated as the symptoms are nonspecific. The quickest and easiest laboratory test to provide an estimate of exposure is by measuring an absolute lymphocyte count is. Cytogenetic dosimetry, the gold standard, relies on predictable and standardized effects of radiation on deoxyribonucleic acid (DNA) replication in cultured lymphocytes.
Treatment of Acute Radiation Syndrome (ARS) focuses on reducing and treating infections, maintaining hydration, and treating injuries and burns, surgery for patients with life threatening disease. Some patients may benefit from treatments that help the bone marrow recover its function. Supportive care saves lives when it comes to acute radiation syndrome. The lower the radiation dose, the more likely it is that the person will recover from ARS. For survivors of ARS, the recovery process may last from several weeks up to 2 years. Prevention of thyroid cancer must be a priority. All children and pregnant women must be offered potassium iodide to protect the thyroid from the uptake of radioactive iodine.
Acute Radiation Syndrome Emerging Drugs Chapters
This segment of the Acute Radiation Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Radiation Syndrome Emerging Drugs
HemaMax™ is based on recombinant human interleukin-12 (IL-12) and is a broad-spectrum biologic therapy. IL-12 is a heterodimeric cytokine that has been shown to play an essential role in regulating inflammatory responses, including an innate resistance to infection and an ability to stimulate the production of interferon-gamma from natural killer cells, macrophages and T-cells. IL-12 also has shown resistance to many pathogens and to transplantable and chemically induced tumors.
- Recilisib: Onconova Therapeutics
Recilisib is a protein kinase inhibitor based small molecule with radiation protection properties. It addresses the need for medical countermeasures to treat the effects of acute radiation syndromes (ARS), specifically radiation-induced cytopenia. Recilisib employs a novel mechanism of action that involves intracellular signaling and DNA damage repair pathways. In pre-clinical studies, cells treated with Recilisib sustained less DNA damage upon exposure to ionizing radiation in comparison to untreated cells.
Further product details are provided in the report……..
Acute Radiation Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Acute Radiation Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acute Radiation Syndrome
- There are approx. 10+ key companies which are developing the therapies for Acute Radiation Syndrome. The companies which have their Acute Radiation Syndrome drug candidates in the most advanced stage, i.e. phase II include, HemaMax.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Acute Radiation Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Acute Radiation Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Radiation Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Radiation Syndrome drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Acute Radiation Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Acute Radiation Syndrome.
- In May 2020, Cellphire, announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its platelet-based freeze-dried hemostatic, Thrombosomes®, for treatment of acute radiation syndrome (ARS).
Acute Radiation Syndrome Report Insights
- Acute Radiation Syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Acute Radiation Syndrome Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acute Radiation Syndrome drugs?
- How many Acute Radiation Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Radiation Syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Radiation Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute Radiation Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Onconova Therapeutics
- Pluristem Therapeutics
- Valenta Pharmaceuticals
- Humanetics Corporation
- Cleveland BioLabs
- Chrysalis BioTherapeutics
- iNtRON Biotechnology
- PLX R18
- Myelo 001